Locametz (kit for Ga-68 gozetotide)
Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.
Overview
Locametz was approved by the FDA on 23 March 2022, alongside Pluvicto (lutetium-177 vipivotide tetraxetan), with an explicit indication for selecting patients with metastatic castration-resistant prostate cancer for PSMA-directed therapy, as well as for initial staging and biochemical recurrence. The European Commission approved it in December 2022. It is manufactured by Advanced Accelerator Applications, the Novartis radiopharmaceutical unit, and was the first PSMA PET agent approved in the EU. The scan-then-treat pairing is the template for theranostics.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2022 | PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy |
| EU | 2022 | PSMA PET in prostate cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Notes
top- What a result means: enough PSMA uptake on the scan is required before Pluvicto can be given; a scan without uptake means the drug is unlikely to work.
Latest papers
topQuery for this drug: (TITLE:"Locametz" OR ABSTRACT:"Locametz" OR TITLE:"kit for Ga-68 gozetotide" OR ABSTRACT:"kit for Ga-68 gozetotide") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Locametz (kit for Ga-68 gozetotide), not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductFludeoxyglucose F-18 (FDG)
Shares PET/CT and the tag test.
- ProductPaige Prostate Detect
Shares Prostate cancer and the tag test.
- ProductOncotype DX Genomic Prostate Score
Shares Prostate cancer and the tag test.
- ProductProlaris
Shares Prostate cancer and the tag test.
- ProductBRACAnalysis CDx
Shares Prostate cancer and the tag test.
- PersonMichael J. Morris
Shares VISION, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
- CompanyClarity Pharmaceuticals
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonA. Oliver Sartor
Shares VISION, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.